A phase 3 study of TNX-102 SL for the treatment of Post traumatic stress disorders (PTSD) in police in Kenya

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 07 Apr 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

04 Apr 2023 According to a Tonix Pharmaceuticals, company has received regulatory clearance in Kenya, which will allow it to rapidly restart the PTSD program at the appropriate time.
14 May 2022 According to a Tonix Pharmaceuticals Holding Corp media release, company has completed a meeting with the FDA to discuss potential new endpoints for the treatment of PTSD and expects to begin enrolling a Phase 2 study of TNX-102 SL in police in Kenya in the first half of 2022.
09 Aug 2021 According to a Tonix Pharmaceuticals Inc media release, the company expects to initiate patient enrollment in the fourth quarter of 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com